Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy

Journal:
Cell Stem Cell
Published:
DOI:
10.1016/j.stem.2025.05.007
Affiliations:
3
Authors:
20
Go to article
Institutions Authors Share
Fate Therapeutics, Inc., United States of America (USA)
15.000000
15.000000
 0.75
Ono Pharmaceutical Co., Ltd., Japan
4.000000
 0.20
Tohoku University, Japan
1.000000
 0.05
Interested in Oncology and Carcinogenesis?